To evaluate the effect of oral nimodipine on reperfusion in acute ischemic cortical stroke.
- Nimodipine (Nimotop®)Drug
Intervention Desc: Calcium channel blocker (L-type calcium channels)
Prospective, double-blind, randomized trial of 50 patients.
Patients were randomized to receive either nimodipine 120 mg/d orally in 4 divided doses (30 mg every 6 hours) or an equivalent regimen of placebo for 14 days.
|Type||Measure||Time Frame||Safety Issue|
|Primary||CBF was assessed with the use of HMPAO SPECT prior to initiation of therapy, 24 hours after pretherapy scan and at 3 months. Neurological impairment was assessed concurrently with SPECT studies by a modified Canadian Neurological Scale (CNS). Functional disability and tissue loss were measured at 3 months by the Barthel Index (BI) and CT, respectively.|